Artwork

Proactive Investors에서 제공하는 콘텐츠입니다. 에피소드, 그래픽, 팟캐스트 설명을 포함한 모든 팟캐스트 콘텐츠는 Proactive Investors 또는 해당 팟캐스트 플랫폼 파트너가 직접 업로드하고 제공합니다. 누군가가 귀하의 허락 없이 귀하의 저작물을 사용하고 있다고 생각되는 경우 여기에 설명된 절차를 따르실 수 있습니다 https://ko.player.fm/legal.
Player FM -팟 캐스트 앱
Player FM 앱으로 오프라인으로 전환하세요!

Paul Romness Discusses OS Therapies' IPO & Clinical Advancement

7:49
 
공유
 

Manage episode 436663122 series 2891889
Proactive Investors에서 제공하는 콘텐츠입니다. 에피소드, 그래픽, 팟캐스트 설명을 포함한 모든 팟캐스트 콘텐츠는 Proactive Investors 또는 해당 팟캐스트 플랫폼 파트너가 직접 업로드하고 제공합니다. 누군가가 귀하의 허락 없이 귀하의 저작물을 사용하고 있다고 생각되는 경우 여기에 설명된 절차를 따르실 수 있습니다 https://ko.player.fm/legal.
OS Therapies CEO Paul Romness joined Steve Darling from Proactive to share news the company has been accepted into Johnson & Johnson Innovation – JLABS, a prestigious platform that supports innovation in the life sciences sector. Through this membership, OS Therapies aims to advance its tunable Antibody Drug Conjugate (ADC) linker-based platform into clinical development. This platform utilizes pH-sensitive linkers and coating technology designed to reduce off-target effects, thereby improving safety and increasing the number and diversity of therapeutic payloads that can be delivered. The tunable ADC platform being developed by OS Therapies holds the promise of offering enhanced efficacy compared to other ADCs currently available or in development. The drug candidates produced using this platform benefit from a unique linker technology, creating new intellectual property for both novel and off-patent targeting antibodies and drug payloads. In addition to this significant milestone, Romness announced that OS Therapies has added Dr. Borys Shor, PhD, to its Antibody Drug Conjugate Advisory Board. Dr. Shor brings over 20 years of experience in oncology discovery programs, particularly in leading preclinical discovery and development efforts for small molecule kinase inhibitors, biologics, and nanoparticles at major pharmaceutical and biotech companies. In his advisory role, Dr. Shor will guide OS Therapies in selecting the most appropriate antibodies and payloads for development using the company's proprietary pH-sensitive SiLinker™ silicone linker technology. These strategic advancements mark a pivotal moment for OS Therapies as it moves closer to bringing innovative and effective cancer therapies to the market. #proactiveinvestors #ostherapies #nyseamerican #ostx #pharma #Immunotherapy #CancerResearch #BiotechIPO #CancerTreatment #Osteosarcoma #BiotechInnovation #PaulRomness #ADCtechnology #ProactiveInvestors#invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews
  continue reading

613 에피소드

Artwork
icon공유
 
Manage episode 436663122 series 2891889
Proactive Investors에서 제공하는 콘텐츠입니다. 에피소드, 그래픽, 팟캐스트 설명을 포함한 모든 팟캐스트 콘텐츠는 Proactive Investors 또는 해당 팟캐스트 플랫폼 파트너가 직접 업로드하고 제공합니다. 누군가가 귀하의 허락 없이 귀하의 저작물을 사용하고 있다고 생각되는 경우 여기에 설명된 절차를 따르실 수 있습니다 https://ko.player.fm/legal.
OS Therapies CEO Paul Romness joined Steve Darling from Proactive to share news the company has been accepted into Johnson & Johnson Innovation – JLABS, a prestigious platform that supports innovation in the life sciences sector. Through this membership, OS Therapies aims to advance its tunable Antibody Drug Conjugate (ADC) linker-based platform into clinical development. This platform utilizes pH-sensitive linkers and coating technology designed to reduce off-target effects, thereby improving safety and increasing the number and diversity of therapeutic payloads that can be delivered. The tunable ADC platform being developed by OS Therapies holds the promise of offering enhanced efficacy compared to other ADCs currently available or in development. The drug candidates produced using this platform benefit from a unique linker technology, creating new intellectual property for both novel and off-patent targeting antibodies and drug payloads. In addition to this significant milestone, Romness announced that OS Therapies has added Dr. Borys Shor, PhD, to its Antibody Drug Conjugate Advisory Board. Dr. Shor brings over 20 years of experience in oncology discovery programs, particularly in leading preclinical discovery and development efforts for small molecule kinase inhibitors, biologics, and nanoparticles at major pharmaceutical and biotech companies. In his advisory role, Dr. Shor will guide OS Therapies in selecting the most appropriate antibodies and payloads for development using the company's proprietary pH-sensitive SiLinker™ silicone linker technology. These strategic advancements mark a pivotal moment for OS Therapies as it moves closer to bringing innovative and effective cancer therapies to the market. #proactiveinvestors #ostherapies #nyseamerican #ostx #pharma #Immunotherapy #CancerResearch #BiotechIPO #CancerTreatment #Osteosarcoma #BiotechInnovation #PaulRomness #ADCtechnology #ProactiveInvestors#invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews
  continue reading

613 에피소드

Alle episoder

×
 
Loading …

플레이어 FM에 오신것을 환영합니다!

플레이어 FM은 웹에서 고품질 팟캐스트를 검색하여 지금 바로 즐길 수 있도록 합니다. 최고의 팟캐스트 앱이며 Android, iPhone 및 웹에서도 작동합니다. 장치 간 구독 동기화를 위해 가입하세요.

 

빠른 참조 가이드